Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

Viking Therapeutics (VKTX) has an average broker recommendation (ABR) of 1.22, approximating a Strong Buy, with 88.9% of recommendations being Strong Buy; however, the article suggests investors should be cautious, as brokerage recommendations can be biased and may not accurately predict stock performance. The Zacks Rank, based on earnings estimate revisions, is presented as a potentially more reliable indicator, and VKTX currently holds a Zacks Rank #3 (Hold), with the consensus earnings estimate unchanged at -$1.86, suggesting near-term performance in line with the broader market.

Analysis

Viking Therapeutics (VKTX) presents a bifurcated outlook based on available analytical tools. The company currently holds an Average Brokerage Recommendation (ABR) of 1.22 on a 1-to-5 scale, positioning it between a Strong Buy and Buy. This ABR is derived from the recommendations of 18 brokerage firms, of which 16, or 88.9%, rate VKTX as a Strong Buy. However, a degree of caution is warranted, as the article highlights potential systemic positive bias in sell-side analyst ratings due to brokerage firms' vested interests; research indicates a far higher ratio of 'Strong Buy' to 'Strong Sell' recommendations industry-wide. Contrasting with the ABR, Viking Therapeutics carries a Zacks Rank #3 (Hold). This rank is determined by a quantitative model focused on earnings estimate revisions, which are empirically correlated with near-term stock price movements. The Zacks Consensus Estimate for VKTX's current-year earnings has remained unchanged at -$1.86 over the past month, suggesting stable but not improving analyst sentiment on its earnings prospects, which supports the 'Hold' rating and implies the stock may perform in line with the broader market in the near term.

Key Decisions for Investors

• Investors should temper enthusiasm from the strong ABR of 1.22 for Viking Therapeutics by considering the more cautious Zacks Rank #3 (Hold), which reflects unchanged earnings estimates.
• The stability of the Zacks Consensus Estimate at -$1.86 suggests that VKTX may track broader market performance in the near term, warranting a neutral stance rather than an aggressively bullish one based solely on ABR.
• It is advisable to prioritize analysis of earnings estimate revisions and the Zacks Rank for VKTX as potentially more objective and timely indicators of future stock performance, rather than relying exclusively on brokerage recommendations which may carry inherent biases.